Filtered By:
Cancer: Prostate Cancer
Therapy: Endocrine Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 64 results found since Jan 2013.

Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
CONCLUSION: Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.PMID:37719086 | PMC:PMC10505079 | DOI:10.1155/2023/2473075
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Qianqian Wang Chunxaing Feng Yuchun Chen Tianming Peng Yong Li Kunlin Wu Xiaoyong Pu Hanzhong Chen Jiumin Liu Source Type: research

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
Cancer Res Commun. 2023 Jul 27;3(7):1378-1396. doi: 10.1158/2767-9764.CRC-23-0111. eCollection 2023 Jul.ABSTRACTThe pro-oncogenic activities of estrogen receptor alpha (ERα) drive breast cancer pathogenesis. Endocrine therapies that impair the production of estrogen or the action of the ERα are therefore used to prevent primary disease metastasis. Although recent successes with ERα degraders have been reported, there is still the need to develop further ERα antagonists with additional properties for breast cancer therapy. We have previously described a benzothiazole compound A4B17 that inhibits the proliferation of and...
Source: Cell Research - July 31, 2023 Category: Cytology Authors: Mengwu Pan Valeria Solozobova Nane C Kuznik Nicole Jung Simone Gr äßle Victor Gourain Yvonne M Heneka Christina A Cramer von Clausbruch Olaf Fuhr Ravi S N Munuganti Danilo Maddalo Christine Blattner Antje Neeb Adam Sharp Laura Cato Carsten Weiss Rinath Source Type: research

Advances in bio-immunotherapy for castration-resistant prostate cancer
J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05152-9. Online ahead of print.ABSTRACTProstate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change...
Source: Clinical Prostate Cancer - July 17, 2023 Category: Cancer & Oncology Authors: Canling Lin Yonghui Chen Liji Shi Huarong Lin Hongmei Xia Weihua Yin Source Type: research

Effect of docetaxel added to bicalutamide in Hormone-Na ïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
CONCLUSION: Docetaxel improved PFS in patients starting bicalutamide due to PSA relapse after local therapy or localized disease without local therapy. Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to endocrine therapies may be justified if longer follow-up will show increased metastatic-free survival.PMID:37073813 | DOI:10.1080/0284186X.2023.2199940
Source: Acta Oncologica - April 19, 2023 Category: Cancer & Oncology Authors: Andreas Josefsson Åsa Jellvert Erik Holmberg Klaus Brasso Peter Meidahl Petersen Sirpa Aaltomaa Marjaana Luukkaa Paul Verhagen Ronald de Wit G öran Ahlgren Ove Andr én Enrique Castellanos Mihalj Seke Anders Widmark Jan-Erik Damber SPCG14-investigators Source Type: research

Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis of randomized controlled trials
ConclusionsThis systematic review and meta-analysis found superior efficacy associated with adding endocrine therapy to SRT compared with SRT alone in patients with biochemical recurrence after RP. Additional endocrine therapy is safe and feasible for patients with biochemical recurrence after RP.Systematic review registrationhttps://www.crd.york.ac.uk/prospero, identifier (CRD42022365432).
Source: Frontiers in Oncology - January 24, 2023 Category: Cancer & Oncology Source Type: research

Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Survey among Urologists in Switzerland, Germany, and Austria
J Clin Med. 2023 Jan 13;12(2):638. doi: 10.3390/jcm12020638.ABSTRACTMedication-related osteonecrosis of the jaw (MRONJ) is a potentially preventable adverse side effect of mainly antiresorptive drugs. MRONJ is expected to become a growing clinical problem due to the aging population and the increasing number of patients requiring antiresorptive agents. Knowledge and awareness about MRONJ and elimination of the oral and dental risk factors before starting antiresorptive therapy (AR) are fundamental to reducing the incidence of MRONJ. In urology, ARs are used primarily in patients suffering from bone metastases due to prosta...
Source: Clinical Prostate Cancer - January 21, 2023 Category: Cancer & Oncology Authors: Salvatore Calderaro Kathrin Bausch C éline Tourbier Christian Wetterauer Florian M Thieringer Britt-Isabelle Berg Source Type: research

Clinical efficacy of neoadjuvant chemohormonal therapy combined with laparoscopic radical prostatectomy in high-risk Prostate Cancer
CONCLUSION: NCHT combined with laparoscopic radical prostatectomy is a safe and effective treatment for high-risk PCa, which is worthy of promotion in clinical practice.PMID:36415258 | PMC:PMC9676598 | DOI:10.12669/pjms.38.8.5469
Source: Cancer Control - November 23, 2022 Category: Cancer & Oncology Authors: Peng Zhang Shengyong Cai Chengquan Yan Lin Li Source Type: research

IJERPH, Vol. 19, Pages 15486: Intermittent Use of Anti-Hormonal Agents for the Endocrine Therapy of Sex-Hormone-Dependent Breast and Prostate Cancer: A Protocol for a Systematic Review
üs Therapies with the continuous administration of anti-hormonal agents in sex-hormone-dependent malignancies such as prostate and breast carcinomas often lead to the development of resistant tumor cells. A systematic evaluation of the use and effects of the intermittent application of endocrine therapy could provide information on the state of knowledge in this research area. PubMed, Cochrane Library, Embase, and Web of Science will be systematically searched using pretested search strategies. Randomized and non-randomized controlled trials, pragmatic trials, case–control, and comparative cohort studies...
Source: International Journal of Environmental Research and Public Health - November 22, 2022 Category: Environmental Health Authors: Keszty üs K ämpfer Keszty üs Tags: Protocol Source Type: research

Steroidogenesis in castration-resistant prostate cancer
Urol Oncol. 2022 Nov 11:S1078-1439(22)00397-0. doi: 10.1016/j.urolonc.2022.10.018. Online ahead of print.ABSTRACTCastration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed. However, primary or acquired resistance to these ARPIs occurs; in turn attributable, at least in part, to the maintained androgen milieu despite intensive suppres...
Source: Urologic Oncology - November 14, 2022 Category: Urology & Nephrology Authors: Masaki Shiota Satoshi Endo Leandro Blas Naohiro Fujimoto Masatoshi Eto Source Type: research